Understanding human TRPV1 polymodal activation

了解人类 TRPV1 多模式激活

基本信息

  • 批准号:
    10521997
  • 负责人:
  • 金额:
    $ 38.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-15 至 2027-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary The goal of the proposed research is to understand the polymodal activation of TRPV1, specifically its activation by heat, protons, and chemical ligands. Understanding the molecular mechanisms that underlie TRPV1 function has significant implications in human health. TRPV1 is a polymodally regulated ion channel that is activated by many diverse stimuli, including heat, protons (low pH), and chemical ligands, like capsaicin, the pungent vanilloid from chili peppers. Over the past decade, there has been significant interest in developing TRPV1 antagonists to combat many types of pain and other relevant indications. One of the main complications in TRPV1 therapeutic intervention is that antagonists commonly dysregulate body temperature. Recent computational modeling and meta-analysis of human clinical trials suggest which modes of TRPV1 should be targeted for the development of analgesic antagonists that mitigate off-target effects. This proposal aims to dissect the independence, interdependence, and crosstalk between canonical TRPV1 activation modes and decipher the respective mechanisms. Nuclear magnetic resonance spectroscopy (NMR) and electrophysiology techniques will be used to achieve these goals. These data will be used to understand which TRPV1 regions underlie particular functions and illuminate allostery, cooperativity, and crosstalk between activation modes. To achieve these goals, two specific aims will be carried out. Aim 1 will focus on the characterization of a minimal TRPV1 construct inspired from natural TRPV1-isoforms that recapitulates the features of the full-length channel with electrophysiology and NMR studies. Additionally, this aim will provide the first structures of a human TRPV1 domain. A membrane domain that is responsible for ligand binding and involved in thermosensing. The structural studies will access non-cryogenic temperatures giving rise to information about the mechanism of thermosensing. These mechanistic and structural studies will be validated and contextualized with cellular studies. Aim 2 will focus on dissecting the allostery and crosstalk between TRPV1 heat, proton, and ligand modes of activation. One series of experiments will rely on validating computational predictions of human TRPV1 allosteric networks with whole- cell patch-clamp measurements. Another set of experiments will leverage chemical ligands from preclinical experiments and clinical trials that will be used with mutagenesis to identify ligand binding sites and how TRPV1 mode selectivity is achieved. The last sub-aim will employ an NMR-detected ligand screen of TRPV1 agonists and antagonists which will be subjected to emerging statistical analysis and learning techniques to generate methodologies capable of predicting which modes of activity TRPV1 modulators will activate. Significant preliminary electrophysiology and NMR data coupled with computational analysis indicate the feasibility of these aims during the timeframe of this proposal. The proposed biophysical and functional TRPV1 studies aim to better understand the molecular mechanisms that govern the function and complicate druggability and are anticipated to guide the development of the next generation of TRPV1 antagonists.
项目摘要 这项研究的目的是了解TRPV 1的多模式激活,特别是它的激活 通过热量质子和化学配体了解TRPV 1功能的分子机制 对人类健康有重大影响。TRPV 1是一种多模态调节的离子通道,由 许多不同的刺激,包括热,质子(低pH值)和化学配体,如辣椒素,辛辣的香草素 从红辣椒。在过去的十年中,人们对开发TRPV 1拮抗剂产生了极大的兴趣 以对抗多种类型的疼痛和其他相关适应症。TRPV 1治疗的主要并发症之一是 干预是拮抗剂通常失调体温。最近的计算模型和 人体临床试验的荟萃分析表明,TRPV 1的哪些模式应作为开发的目标 减轻脱靶效应的镇痛拮抗剂。这项建议旨在剖析独立性, 相互依赖性和典型TRPV 1激活模式之间的串扰,并破译各自的 机制等将使用核磁共振光谱(NMR)和电生理学技术 来实现这些目标。这些数据将用于了解TRPV 1区域的特定功能 并阐明激活模式之间的变构性、协同性和串扰。为了实现这些目标,两个 将实现具体目标。目标1将集中在一个最小的TRPV 1结构的表征启发 来自天然TRPV 1-同种型,其用电生理学再现全长通道的特征, NMR研究。此外,这一目标将提供人类TRPV 1结构域的第一个结构。的膜 负责配体结合并参与热敏的结构域。结构研究将访问 非低温温度引起关于热敏机理的信息。这些 机制和结构研究将得到验证,并与细胞研究相结合。目标2将侧重于 剖析TRPV 1热、质子和配体激活模式之间的变构和串扰。一个系列 的实验将依赖于验证人类TRPV 1变构网络的计算预测, 细胞膜片钳测量。另一组实验将利用临床前的化学配体 实验和临床试验,将用于诱变,以确定配体结合位点和如何TRPV 1 实现了模式选择性。最后一个子目标将采用NMR检测的TRPV 1激动剂配体筛选 和拮抗剂,将受到新兴的统计分析和学习技术,以产生 能够预测TRPV 1调节剂将激活哪种活性模式的方法。显著 初步的电生理学和核磁共振数据加上计算分析表明,这些可行性, 在这个时间段内,我们的目标是。拟议的生物物理和功能TRPV 1研究旨在更好地 了解控制功能和复杂化可药用性的分子机制, 指导下一代TRPV 1拮抗剂的开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wade D. Van Horn其他文献

Mechanistic and Structural Studies of PIRT Regulation of TRPM8
  • DOI:
    10.1016/j.bpj.2019.11.2338
  • 发表时间:
    2020-02-07
  • 期刊:
  • 影响因子:
  • 作者:
    Wade D. Van Horn;Dustin D. Luu;Minjoo Kim;Jacob K. Hilton;Camila Montano
  • 通讯作者:
    Camila Montano
VITAMIN K SUBSTANCES
维生素 K 物质
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Wade D. Van Horn
  • 通讯作者:
    Wade D. Van Horn
Delivery of nonbiologically-compatible membrane protein constructs to mammalian cells for functional characterization
  • DOI:
    10.1016/j.bpj.2022.11.1913
  • 发表时间:
    2023-02-10
  • 期刊:
  • 影响因子:
  • 作者:
    Wade D. Van Horn;Helen F. Mann;Karan H. Shah;Dustin D. Luu;Aerial M. Pratt;Cade F. Bennett;Katherine R. Clowes;Charles R. Sanders
  • 通讯作者:
    Charles R. Sanders
VKORC1 ER mislocalization causes rare disease.
VKORC1 ER 错误定位会导致罕见疾病。
  • DOI:
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    20.3
  • 作者:
    Wade D. Van Horn
  • 通讯作者:
    Wade D. Van Horn
Characterization of HTRPM8 Conformational Dynamic Utilizing Solution NMR
  • DOI:
    10.1016/j.bpj.2019.11.2336
  • 发表时间:
    2020-02-07
  • 期刊:
  • 影响因子:
  • 作者:
    Mubark Mebrat;Jacob K. Hilton;Danielle Morelan;Wade D. Van Horn
  • 通讯作者:
    Wade D. Van Horn

Wade D. Van Horn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wade D. Van Horn', 18)}}的其他基金

Understanding human TRPV1 polymodal activation
了解人类 TRPV1 多模式激活
  • 批准号:
    10634726
  • 财政年份:
    2022
  • 资助金额:
    $ 38.31万
  • 项目类别:
Molecular Mechanisms and Regulation Networks of TRPM8
TRPM8的分子机制和调控网络
  • 批准号:
    10396096
  • 财政年份:
    2021
  • 资助金额:
    $ 38.31万
  • 项目类别:
Molecular Mechanisms and Regulation Networks of TRPM8
TRPM8的分子机制和调控网络
  • 批准号:
    10795242
  • 财政年份:
    2021
  • 资助金额:
    $ 38.31万
  • 项目类别:
Molecular Mechanisms and Regulation Networks of TRPM8
TRPM8的分子机制和调控网络
  • 批准号:
    10206573
  • 财政年份:
    2021
  • 资助金额:
    $ 38.31万
  • 项目类别:
Molecular Mechanisms and Regulation Networks of TRPM8
TRPM8的分子机制和调控网络
  • 批准号:
    10569021
  • 财政年份:
    2021
  • 资助金额:
    $ 38.31万
  • 项目类别:
PIRT Family Modulation of TRPM8
TRPM8 的 PIRT 系列调制
  • 批准号:
    8962682
  • 财政年份:
    2015
  • 资助金额:
    $ 38.31万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 38.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 38.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了